"We are dedicated to making iPSC technology the industry standard for the early introduction of human pharmacology into the drug discovery process."
-Michael C. Venuti, Ph.D., CEO, iPierian
Media Inquiries
If you are a member of the media and have questions about company news announcements, interview requests, or other related inquiries, please contact:
Paul Laland
WeissComm Partners
415.946.1071
plaland@wcpglobal.com
Latest News
07/08/10
iPierian Closes $22 Million Series B Financing Led By Google Ventures
06/15/10
iPierian to Present Data from Induced Pluripotent Stem Cell Program at ISSCR 8th Annual Meeting
02/22/10
iPierian Appoints Dr. Michael Venuti as President and Chief Scientific Officer